LambdaVision, Inc.

@lambdavision.bsky.social

Developing a protein-based artificial retina to restore meaningful vision for the millions of patients blinded by retinal diseases. LambdaVision.com

That’s a wrap on TechConnect! Our CEO Nicole Wagner, Ph.D., and CSO, Jordan Greco, Ph.D., spoke on the future of space-based research, from LambdaVision’s artificial retina to broader applications of bacteriorhodopsin & layer-by-layer manufacturing. Excited to keep pushing innovation forward!

We’re heading to #ASCEND25! On July 23, CEO Nicole Wagner, Ph.D., will join leaders from Space Tango, Voyager, and more to discuss protecting U.S. scientific and commercial leadership in LEO amid ISS transitions. Learn more: bit.ly/4nmgnWu #SpaceBasedResearch

2025 ASCEND

Powered by AIAA, this event features a visionary agenda, inspiring speakers, and a community spirit that welcomes everyone who loves space. Sign up for updates and ASCENDxSeries events throughout the ...

bit.ly

From low-Earth orbit to restoring sight: LambdaVision is leveraging microgravity aboard the International Space Station National Laboratory to pioneer our protein-based artificial retinas. Our CEO, Nicole Wagner, PhD, shares our story in Pharma's Almanac. Read the full article here: bit.ly/42CxuLi

From Space to Sight: Leveraging Microgravity to Enhance Artificial Retina Technology

LambdaVision is harnessing the transformative potential of microgravity aboard the International Space Station to revolutionize artificial retina manufacturing.

bit.ly

The Rare Disease Forum on March 10th, hosted by BioCT & The Jackson Laboratory, will highlight innovations in rare disease diagnostics & treatments. Retinitis pigmentosa (RP) is one such rare disease, underscoring the need for continued research & innovation. Learn more: bit.ly/4ieDdME

2025 Connecticut Rare Disease Forum - BioCT

Join BioCT and The Jackson Laboratory for an afternoon of industry-led discussions on innovation in rare disease diagnostics and treatments, along with the promising...

bit.ly